JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deeks, S. G.
Right arrow Articles by Hecht, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deeks, S. G.
Right arrow Articles by Hecht, F. M.
Journal of Virology, June 2006, p. 6155-6164, Vol. 80, No. 12
0022-538X/06/$08.00+0     doi:10.1128/JVI.00093-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Neutralizing Antibody Responses against Autologous and Heterologous Viruses in Acute versus Chronic Human Immunodeficiency Virus (HIV) Infection: Evidence for a Constraint on the Ability of HIV To Completely Evade Neutralizing Antibody Responses

Steven G. Deeks,1* Becky Schweighardt,2 Terri Wrin,2 Justin Galovich,2 Rebecca Hoh,1 Elizabeth Sinclair,1 Peter Hunt,1 Joseph M. McCune,1 Jeffrey N. Martin,1 Christos J. Petropoulos,2 and Frederick M. Hecht1

Department of Medicine, University of California at San Francisco, and San Francisco General Hospital, San Francisco, California,1 Monogram Biosciences, Inc., San Francisco, California2

Received 13 January 2006/ Accepted 18 February 2006

Acute human immunodeficiency virus (HIV) infection is associated with the rapid development of neutralization escape mutations. The degree to which viral evolution persists in chronic infection has not been well characterized, nor is it clear if all patients develop high-level neutralization antibody escape. We therefore measured neutralizing antibody responses against autologous and heterologous viruses in a cohort of acutely and chronically infected subjects (n = 65). Neutralizing antibody responses against both autologous virus and heterologous viruses were lower among individuals with acute infection than among those with chronic infection. Among chronically infected individuals, there was a negative correlation between the level of neutralizing antibodies against autologous virus and the level of viremia. In contrast, there was a positive correlation between the level of neutralizing antibodies against a panel of heterologous viruses and the level of viremia. Viral evolution, as defined by the presence of higher neutralizing titers directed against earlier viruses than against contemporaneous viruses, was evident for subjects with recent infection but absent for those with chronic infection. In summary, neutralizing antibody responses against contemporaneous autologous viruses are absent in early HIV infection but can be detected at low levels in chronic infection, particularly among those controlling HIV in the absence of therapy. HIV replication either directly or indirectly drives the production of increasing levels of antibodies that cross-neutralize heterologous primary isolates. Collectively, these observations indicate that although HIV continuously drives the production of neutralizing antibodies, there may be limits to the capacity of the virus to evolve continuously in response to these antibodies. These observations also suggest that the neutralizing antibody response may contribute to the long-term control of HIV in some patients while protecting against HIV superinfection in most patients.


* Corresponding author. Mailing address: San Francisco General Hospital, 995 Potrero Avenue, San Francisco, CA 94110. Phone: (415) 476-4082, ext. 404. Fax: (415) 476-6953. E-mail: sdeeks{at}php.ucsf.edu.


Journal of Virology, June 2006, p. 6155-6164, Vol. 80, No. 12
0022-538X/06/$08.00+0     doi:10.1128/JVI.00093-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2006 by the American Society for Microbiology. All rights reserved.